London
· Delayed Price · Currency is GBP · Price in USD TG Therapeutics Statistics
Total Valuation
TG Therapeutics has a market cap or net worth of GBP 3.40 billion. The enterprise value is 3.32 billion.
| Market Cap | 3.40B |
| Enterprise Value | 3.32B |
Important Dates
The next estimated earnings date is Friday, February 28, 2025.
| Earnings Date | Feb 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.08% |
| Shares Change (QoQ) | +0.81% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 133.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 23.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -310.24 |
| EV / Sales | 15.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -158.53 |
Financial Position
The company has a current ratio of 4.59, with a Debt / Equity ratio of 1.32.
| Current Ratio | 4.59 |
| Quick Ratio | 3.65 |
| Debt / Equity | 1.32 |
| Debt / EBITDA | 136.31 |
| Debt / FCF | -9.03 |
| Interest Coverage | -0.03 |
Financial Efficiency
Return on equity (ROE) is -8.05% and return on invested capital (ROIC) is -0.09%.
| Return on Equity (ROE) | -8.05% |
| Return on Assets (ROA) | -0.07% |
| Return on Capital (ROIC) | -0.09% |
| Revenue Per Employee | 619,310 |
| Profits Per Employee | -33,596 |
| Employee Count | 264 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 0.52 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +90.19% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +90.19% |
| 50-Day Moving Average | 31.51 |
| 200-Day Moving Average | 22.80 |
| Relative Strength Index (RSI) | 44.55 |
| Average Volume (20 Days) | 3,845 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.65 |
Income Statement
In the last 12 months, TG Therapeutics had revenue of GBP 197.56 million and -10.72 million in losses. Loss per share was -0.07.
| Revenue | 197.56M |
| Gross Profit | 174.47M |
| Operating Income | -376,781 |
| Pretax Income | -10.36M |
| Net Income | -10.72M |
| EBITDA | -304,409 |
| EBIT | -376,781 |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 254.45 million in cash and 189.37 million in debt, giving a net cash position of 65.08 million.
| Cash & Cash Equivalents | 254.45M |
| Total Debt | 189.37M |
| Net Cash | 65.08M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 143.37M |
| Book Value Per Share | 1.00 |
| Working Capital | 334.97M |
Cash Flow
In the last 12 months, operating cash flow was -20.95 million and capital expenditures -17,906, giving a free cash flow of -20.97 million.
| Operating Cash Flow | -20.95M |
| Capital Expenditures | -17,906 |
| Free Cash Flow | -20.97M |
| FCF Per Share | n/a |
Margins
Gross margin is 88.31%, with operating and profit margins of -0.19% and -5.42%.
| Gross Margin | 88.31% |
| Operating Margin | -0.19% |
| Pretax Margin | -5.24% |
| Profit Margin | -5.42% |
| EBITDA Margin | -0.15% |
| EBIT Margin | -0.19% |
| FCF Margin | n/a |
Dividends & Yields
TG Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.08% |
| Shareholder Yield | -3.08% |
| Earnings Yield | -0.32% |
| FCF Yield | -0.62% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TG Therapeutics has an Altman Z-Score of 1.23. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.23 |
| Piotroski F-Score | n/a |